THOUSAND OAKS, Calif., Oct 23, 2003 -- Amgen Inc. (Nasdaq: AMGN), the world´s largest biotechnology company, has been
named among the top biotechnology and pharmaceutical employers in a
comprehensive survey sponsored by Science magazine for the second consecutive
year. In this year´s survey, Amgen was ranked third, up from eighth place in
According to Science, Amgen´s ascent to the number three spot in the
reader-response survey is primarily based on its leadership´s ability to keep
the organization moving in the right direction, the attribute that responders
ranked as most important in this year´s survey. Out of 42 attributes that
companies were ranked against, ´top leadership that keeps the organization on
track´ replaced ´innovative industry leader´ as the top-ranking attribute this
year, reflecting a shift in reader sentiment from a focus on external or
industry factors to a focus on internal corporate matters.
"At Amgen, we aspire to be the best human therapeutics company,
introducing products that dramatically improve people´s lives," said Roger
Perlmutter, M.D., Ph.D., executive vice president, research and development at
Amgen. "That aspiration is ennobling, challenging and brings a certain
passion to our work. Over the last three years, we´ve made significant
changes in our R&D leadership, linking the R&D organization with drug
development and manufacturing to optimize the delivery of novel therapeutics.
We are pleased that our efforts are being recognized," said Perlmutter.
Founded in 1980, Amgen is a pioneer in the biotechnology industry. Based
on a history of scientific innovation, Amgen launched the first biotechnology
blockbuster products, EPOGEN(R) (Epoetin alfa) and NEUPOGEN(R) (Filgrastim),
and continues to research, identify and develop novel therapeutics to treat
grievous illness. The Company invests heavily in research and development,
having invested 22 percent of total product sales in R&D in 2002, among the
highest reinvestment levels in the biotechnology and pharmaceutical
Areas of research focus include oncology, neurosciences, inflammation,
metabolic disorders and hematology.
According to the publication, the survey includes responses from more than
900 readers of Science, 94 percent of whom work in the pharmaceutical,
biotechnology, and biopharmaceutical industries in the U.S. and Europe. Of
those who participated in the survey, more than 75 percent have an M.D.,
Ph.D., or M.D.-Ph.D. The survey was designed and conducted by Hughes Research
Worldwide (HRW), an independent research and consulting firm specializing in
Amgen is a global biotechnology company that discovers, develops,
manufactures and markets important human therapeutics based on advances in
cellular and molecular biology.
CONTACT: Amgen, Thousand Oaks
Media, (805) 447-4587